齐拉西酮与奥氮平治疗精神分裂症对照研究引起体重和血糖增加的Meta分析

A Meta-analysis of Increased Body Weight and Blood Sugar Induced by Ziprasidone and Oalnzapine for the Treatment of Schizophrenia

目的评价齐拉西酮与奥氮平治疗精神分裂症对照研究期间引起体重和血糖升高的差异。方法应用循证医学方法对符合标准的6项研究进行分析,评价齐拉西酮与奥氮平治疗精神分裂症过程中出现体重增加和血糖升高的差异。结果齐拉西酮组与奥氮平治疗精神分裂症的体重增加发生率分别是4.0%和34.4%,差异有统计学意义(P<0.01),血糖升高的发生率分别是1.3%和23.2%,差异有统计学意义(P<0.01)。结论齐拉西酮和奥氮平虽都是治疗精神分裂症的一种良好的药物,但是它们的副作用,特别是体重增加和血糖升高存在统计学差异。

Objective To assess the difference of incidences of higher body weight and blood sugar induced by Ziprasidone and Oalnzapine for treatment of schizophrenia.Methods Six studies meeting our criteria were analyzed by method of evidence-based medicine.Compare the differences of incidences of higher body weight and blood sugar induced by Ziprasidone and Oalnzapine for treatment of schizophrenia.Results The incidence of higher body weight induced by Ziprasidone and Oalnzapine were 4.0% and 34.4% respectively,the difference was significant（P0.01）.The incidence of higher blood sugar caused by Ziprasione and Oalnzapine were 1.3% and 23.2% respectively,the difference was also significant（P0.01）.Conclusion Both Ziprasidone and Oalnzapine are good drugs for the treatment of patients with schizophrenia,but their side effects,especially increasing body weight and blood sugar are of statistical difference.